{"id":5107,"date":"2024-01-31T00:50:08","date_gmt":"2024-01-31T00:50:08","guid":{"rendered":"https:\/\/economicherald.net\/?p=5107"},"modified":"2024-01-31T00:50:08","modified_gmt":"2024-01-31T00:50:08","slug":"asx-health-stocks-nsb-jumps-11pc-after-quarterly-update-lumos-makes-great-strides-with-fda","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=5107","title":{"rendered":"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA"},"content":{"rendered":"<p>NeuroScientific Biopharma jumps 11.5pc after quarterly update<br \/>\nLumos Diagnostics\u2019s Q2 revenue beats previous quarter<\/p>\n<p>\u00a0<\/p>\n<h2>Neuroscientific Bio\u2019s shares up after update<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/neuroscientific-biopharmaceuticals-nsb\/\">NeuroScientific Biopharma (ASX:NSB)<\/a><\/strong> surged 11.5% this morning after detailing its activities in the last quarter.<\/p>\n<p>In the December quarter, NSB collated all data and requested a<strong> Type B, Pre-IND Meeting with the FDA <\/strong>with regards to <strong>EmtinB<\/strong> \u2013 the company\u2019s lead drug designed to treat neurodegenerative conditions like <strong>Multiple Sclerosis<\/strong> and <strong>Alzheimer\u2019s disease.<\/strong><\/p>\n<p>NSB is currently working with highly experienced consultants in the UK, EU, US and Australia, to gain as much insight from the FDA and confirm that the development plan for the drug is in place.<\/p>\n<p>Meanwhile, results from the Early Phase Clinical Study data of EmtinB are expected in Q1 this year.<\/p>\n<p>Separately, NSB says it continues to evaluate new and promising programs to provide the company with a pipeline of projects.<\/p>\n<p>NeuroScientific\u2019s cash position was $3.34 million as at 31 December. The company says it has maintained a strong cash position with corporate expenses continuing to be carefully managed.<\/p>\n<p>Finally, the level of net cash burn for the March 2024 quarter is expected to be at similar levels as for the December 2023 quarter.<\/p>\n<p>NSB says it wants to preserve cash in the coming months as the work towards the development of EmtinB commences.<\/p>\n<p>\u00a0<\/p>\n<h2>Lumos\u2019s revenue jumps in Q2<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/lumos-diagnostics-ldx\/\">Lumos Diagnostics (ASX:LDX)<\/a><\/strong> rose 5% this morning after reporting that its<strong> Q2 revenue came in at US$1.7 million<\/strong>, versus Q1 revenue US$1.1 million.<\/p>\n<p>The majority of revenue generated during the quarter was from the sales of diagnostic test development services, and contract manufacturing for clients in the company\u2019s <em>Commercial Services<\/em> unit.<\/p>\n<p>Development services included ongoing project work for <em>Hologic, Aptatek, Alden, MicroPak, Food-In-Depth<\/em>. This work is anticipated to continue into future periods.<\/p>\n<p>Meanwhile, Lumos has made great strides with <strong>FebriDx<\/strong>, its rapid, point-of-care test which can be used to detect acute bacterial disease from respiratory infections.<\/p>\n<p>To date, Lumos has received regulatory registrations for the use of FebriDx in the US, UK, Europe, Canada, UAE and Australia.<\/p>\n<p><strong>ViraDx<\/strong>\u00a0 \u2013 Lumos\u2019 rapid point-of-care diagnostic tests for acute respiratory infections caused by the COVID-19, influenza A, and influenza B viruses \u2013 was also granted <strong>US FDA Emergency Use Authorisation (EUA)<\/strong> and a <strong>CLIA Waiver.<\/strong><\/p>\n<p>During the December quarter, Lumos made significant progress in preparation for the launch of ViraDx in the US market.<\/p>\n<p>First orders for ViraDx were delivered in December. And with the US flu season underway, Lumos said it is continuing to receive orders and enquiries.<\/p>\n<p>Key focus areas this year will be building its pipeline of commercial, revenue-generating projects. The strategy here is to accelerate the growth of sustainable revenue streams from its business units, Lumos says.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-nsb-jumps-11pc-after-quarterly-update-lumos-makes-great-strides-with-fda\/\">ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>NeuroScientific Biopharma jumps 11.5pc after quarterly update Lumos Diagnostics\u2019s Q2 revenue beats previous quarter \u00a0 Neuroscientific Bio\u2019s shares up after update NeuroScientific Biopharma (ASX:NSB) surged <a href=\"https:\/\/economicherald.net\/?p=5107\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":5108,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-5107","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=5107\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"NeuroScientific Biopharma jumps 11.5pc after quarterly update Lumos Diagnostics\u2019s Q2 revenue beats previous quarter \u00a0 Neuroscientific Bio\u2019s shares up after update NeuroScientific Biopharma (ASX:NSB) surged [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=5107\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-31T00:50:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA\",\"datePublished\":\"2024-01-31T00:50:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107\"},\"wordCount\":490,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5107#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=5107\",\"name\":\"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg\",\"datePublished\":\"2024-01-31T00:50:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5107\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5107#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=5107","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA - Economic Herald","og_description":"NeuroScientific Biopharma jumps 11.5pc after quarterly update Lumos Diagnostics\u2019s Q2 revenue beats previous quarter \u00a0 Neuroscientific Bio\u2019s shares up after update NeuroScientific Biopharma (ASX:NSB) surged [more...]","og_url":"https:\/\/economicherald.net\/?p=5107","og_site_name":"Economic Herald","article_published_time":"2024-01-31T00:50:08+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=5107#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=5107"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA","datePublished":"2024-01-31T00:50:08+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=5107"},"wordCount":490,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=5107#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=5107#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=5107","url":"https:\/\/economicherald.net\/?p=5107","name":"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=5107#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=5107#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg","datePublished":"2024-01-31T00:50:08+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=5107#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=5107"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=5107#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/NeuroScientific-Biopharma-jumps-10pc-after-quarterly-update.-Picture-Getty-dbHjPl.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=5107#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5107"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5107\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/5108"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}